| Literature DB >> 28415928 |
Jin Young Lee1, Hee Cheol Kim2, Jung Wook Huh2, Woo Seog Sim1, Hyun Young Lim1, Eun Kyung Lee1, Hui Gyeong Park1, Yu Jeong Bang1.
Abstract
Objective This study was performed to investigate the incidence of and potential risk factors for rectal pain after laparoscopic rectal cancer surgery. Methods We retrospectively analyzed data from 300 patients who underwent laparoscopic rectal cancer surgery. We assessed the presence of rectal pain and categorized patients into Group N (no rectal pain) or Group P (rectal pain). Results In total, 288 patients were included. Of these patients, 39 (13.5%) reported rectal pain and 14 (4.9%) had rectal pain that persisted for >3 months. Univariate analysis revealed that patients in Group P had more preoperative chemoradiotherapy, more ileostomies, longer operation times, more anastomotic margins of <2 cm from the anal verge, more anastomotic leakage, and longer hospital stays. Multivariate analysis identified an anastomotic margin of <2 cm from the anal verge and a long operation time as risk factors. The presence of diabetes mellitus was a negative predictor of rectal pain. Conclusions In this study, the incidence of rectal pain after laparoscopic rectal cancer surgery was 13.5%. An anastomotic margin of <2 cm from the anal verge and a long operation time were risk factors for rectal pain. The presence of diabetes mellitus was a negative predictor of rectal pain. Thus, the possibility of postoperative rectal pain should be discussed preoperatively with patients with these risk factors.Entities:
Keywords: Anastomosis; laparoscopic surgery; rectal cancer; rectal pain
Mesh:
Year: 2017 PMID: 28415928 PMCID: PMC5536646 DOI: 10.1177/0300060517693421
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Rectal pain onset (n = 39).
| Postoperative time point | |
|---|---|
| 1 h | 5 (12.8) |
| 1 d | 3 (7.7) |
| 3 d | 11 (28.2) |
| 5 d | 8 (20.5) |
| 1 mo | 6 (15.4) |
| 3 mo | 3 (7.7) |
| 6 mo | 3 (7.7) |
| 12 mo | 0 (0.0) |
All data are presented as n (%) patients.
Potential predictive factors for rectal pain.
| All patients ( | Group N ( | Group P ( | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|---|
| 95% CI | 95% CI | OR | ||||||
| Age, years | 60.7 ± 11.1 | 61.0 ± 11.1 | 58.3 ± 11.0 | 0.949–1.008 | 0.148 | |||
| < 60 | 125 (43.4) | 104 (41.8) | 21 (53.9) | |||||
| ≥60 | 163 (56.6) | 145 (58.2) | 18 (46.2) | |||||
| Sex, M/F | 177/111 | 153/96 | 24/15 | 0.502–2.009 | 0.991 | |||
| Height, cm | 162.1 ± 8.6 | 161.9 ± 8.5 | 163.5 ± 9.6 | 0.982–1.065 | 0.478 | |||
| Weight, kg | 60.7 ± 10.5 | 60.5 ± 10.5 | 61.7 ± 10.5 | 0.979–1.044 | 0.497 | |||
| BMI, kg/m2 | 23.0 ± 3.0 | 23.0 ± 3.0 | 23.0 ± 3.2 | 0.903–1.128 | 0.877 | |||
| <25 | 218 (75.7) | 187 (75.1) | 31 (79.5) | 0.553 | ||||
| ≥25 | 70 (24.3) | 62 (24.9) | 8 (20.5) | |||||
| Charlson comorbidity index | 2.9 ± 1.5 | 2.9 ± 1.5 | 3.0 ± 1.6 | 0.863–1.324 | 0.545 | |||
| Presence of diabetes mellitus | 46 (16.0) | 44 (17.7) | 2 (5.1) | 0.064 | 1.107–28.980 | 0.037 | 5.663 | |
| Preoperative CRT | 63 (21.9) | 46 (18.5) | 17 (43.6)* | 1.678–6.931 | <0.001 | 0.431–3.111 | 0.771 | 1.158 |
| Pathological stage | ||||||||
| I | 104 (36.1) | 88 (35.3) | 16 (41.0) | 0.123–9.781 | 0.450 | |||
| II | 54 (18.8) | 48 (19.4) | 6 (15.4) | 0.077–7.338 | ||||
| III | 104 (36.1) | 93 (37.5) | 11 (28.2) | 0.078–6.452 | ||||
| IV | 25 (8.7) | 19 (7.7) | 6 (15.4) | 0.189–19.039 | ||||
| Preoperative pain (NRS) | 0.6 ± 1.8 | 0.2 ± 1.1 | 0.3 ± 1.2 | 0.830 | ||||
| Operation time, min | 177.0 ± 61.3 | 168.6 ± 55.1 | 230.4 ± 72.1* | 1.008–1.018 | <0.001 | 1.006–1.018 | <0.001 | 1.012 |
| Ileostomy | 61 (24.5) | 45 (18.6) | 16 (41.0)* | 1.489–6.229 | 0.001 | |||
| Maximum tumor size of >4 cm | 92 (36.9) | 81 (32.7) | 11 (28.2) | 0.384–1.708 | 0.580 | |||
| Anastomotic margin of ≤2 cm from anal verge | 39 (15.7) | 23 (9.2) | 16 (41.0)* | 3.155–14.683 | <0.001 | 2.475–13.542 | <0.001 | 5.790 |
| Length of hospital stay, days | 7.7 ± 5.4 | 7.4 ± 4.3 | 10.1 ± 9.7* | 1.013–1.117 | 0.013 | 0.966–1.109 | 0.324 | 1.035 |
| Anastomotic leakage | 13 (4.5) | 8 (3.2) | 5 (12.8)* | 1.370–14.326 | 0.013 | 0.454–12.280 | 0.306 | 2.362 |
All data are presented as mean ± SD or n (%) patients. M/F: male/female; BMI: body mass index; CRT: chemoradiotherapy; NRS: numeric rating scale; CI: confidence interval; OR: odds ratio, Group N: patients without postoperative rectal pain; Group P: patients with postoperative rectal pain. *P < 0.05 compared with Group N.
Abdominal pain severity and opioid consumption.
| Group N ( | Group P ( | ||
|---|---|---|---|
| Pain severity (NRS) | |||
| 1 h postoperatively | 5.5 ± 1.0 | 5.6 ± 1.1 | 0.794 |
| 1 d postoperatively | 5.9 ± 1.5 | 6.1 ± 2.2 | 0.484 |
| 3 d postoperatively | 4.5 ± 1.8 | 5.1 ± 2.0 | 0.084 |
| 5 d postoperatively | 3.3 ± 1.2 | 3.9 ± 2.0 | 0.125 |
| Opioid consumption, µg | |||
| Intraoperative | 87.0 ± 52.0 | 90.2 ± 55.9 | 0.737 |
| 1 h postoperatively | 49.9 ± 26.6 | 52.6 ± 31.4 | 0.627 |
| 1 d postoperatively | 80.8 ± 77.1 | 109.2 ± 130.8 | 0.194 |
| 3 d postoperatively | 80.5 ± 82.8 | 115.5 ± 133.5 | 0.120 |
| 5 d postoperatively | 79.0 ± 49.3 | 118.6 ± 79.0* | 0.004 |
All data are presented as mean ± SD. Group N: patients without postoperative rectal pain; Group P: patients with postoperative rectal pain; NRS: numeric rating scale. *P < 0.05 compared with Group N.
Rectal pain severity and management in Group P.
| Patient No. | Postoperative time point | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 h | 1 d | 3 d | 5 d | 1 mo | 3 mo | 6 mo | 12 mo | ||||
| 1 | 3 | 0 | 0 | 0 | 6 | 5 | 5 | 2 | |||
| PCA | Opioids | Anticonvulsants Opioids | Anticonvulsants Antidepressants Opioids | Opioids Analgesics | Opioids Analgesics | ||||||
| 2 | 0 | 0 | 4 | 0 | 5 | 5 | 4 | 2 | |||
| PCA | Opioids | Opioids | Opioids | Anticonvulsants Analgesics | Anticonvulsants | ||||||
| 3 | 0 | 0 | 4 | 0 | 4 | 0 | 1 | 1 | |||
| PCA | Opioids | Rehabilitation | Observation | ||||||||
| 4 | 0 | 0 | 0 | 0 | 3 | 0 | 4 | 2 | |||
| PCA | Opioids | Observation | Anticonvulsants Opioids | Anticonvulsants | |||||||
| 5 | 3 | 0 | 0 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 6 | 0 | 0 | 0 | 6 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 7 | 0 | 0 | 6 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 8 | 0 | 0 | 0 | 8 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 9 | 0 | 0 | 4 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 10 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 1 | |||
| PCA | Opioids | Observation | Opioids | Observation | |||||||
| 11 | 0 | 0 | 0 | 0 | 0 | 6 | 5 | ||||
| PCA | Opioids | Observation | Opioids | ||||||||
| 12 | 0 | 0 | 4 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 13 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | |||
| PCA | Opioids | Observation | Opioids | Observation | |||||||
| 14 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | |||
| PCA | Opioids | Observation | |||||||||
| 15 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | |||
| PCA | Opioids | Observation | |||||||||
| 16 | 0 | 0 | 4 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 17 | 0 | 0 | 0 | 2 | 4 | 4 | 2 | 2 | |||
| PCA | Opioids | Opioids | Rehabilitation | Observation | |||||||
| 18 | 0 | 6 | 0 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 19 | 0 | 0 | 6 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 20 | 3 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | |||
| PCA | Opioids | Observation | Rehabilitation | Observation | |||||||
| 21 | 0 | 0 | 0 | 6 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 22 | 0 | 0 | 4 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 23 | 0 | 0 | 0 | 0 | 5 | 5 | 5 | 2 | |||
| PCA | Opioids | Opioids | Rehabilitation | ||||||||
| 24 | 0 | 0 | 3 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 25 | 0 | 0 | 0 | 0 | 4 | 5 | 5 | 3 | |||
| PCA | Opioids | Opioids | |||||||||
| 26 | 0 | 4 | 0 | 0 | 4 | 1 | 4 | 3 | |||
| PCA | Opioids | Opioids | Analgesics | Opioids | Rehabilitation | ||||||
| 27 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | |||
| PCA | Opioids | Observation | |||||||||
| 28 | 0 | 0 | 0 | 4 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 29 | 0 | 0 | 0 | 5 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 30 | 0 | 0 | 0 | 4 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 31 | 0 | 0 | 6 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 32 | 0 | 0 | 6 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 33 | 0 | 4 | 0 | 4 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 35 | 0 | 0 | 0 | 0 | 5 | 6 | 5 | 0 | |||
| PCA | Opioids | Opioids | Observation | ||||||||
| 36 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 2 | |||
| PCA | Opioids | Observation | Opioids | Rehabilitation | |||||||
| 37 | 7 | 0 | 0 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 38 | 0 | 0 | 0 | 3 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
| 39 | 5 | 0 | 0 | 0 | 0 | ||||||
| PCA | Opioids | Observation | |||||||||
Pain severity is presented as the numeric rating scale score. PCA: patient-controlled analgesia.